Congratulations to Pacira BioSciences, Inc. on the recently published positive 104-week safety and efficacy data from their Phase 1 clinical trial for knee osteoarthritis gene therapy with PCRX-201! This is a significant achievement that brings us closer to transformative solutions for patients. PCRX-201, which was originally developed by GQ Bio Therapeutics, demonstrated durable pain relieve across all levels of disease severity for at least 2 years following a single injection. We are excited about the further development of PCRX-201 with an anticipated start of a Phase 2 clinical trial in 2025.
Today Pacira announced new data will be presented by Dr. stanley cohen at the American College of Rheumatology Convergence 2024 meeting that demonstrates how we are unlocking the ability for locally-administered gene therapy to treat common diseases like osteoarthritis of the knee that affect millions of people. This marks another step forward in our commitment to pursuing innovative non-opioid solutions to transform the lives of patients. Better is possible. #ACR24 #PaciraProud Learn more about the study here: https://bit.ly/48QVxYz